TEL AVIV, ISRAEL, May 1, 2007 – Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the first quarter ended March 31, 2007.
“The achievements of the past few months have clearly begun to demonstrate our unique and broadly applicable discovery capabilities and the value now existing from our long-term science-based and infrastructure-building efforts,” said Alex Kotzer, President and Chief Executive Officer of Compugen. “Since the beginning of the year, we have announced a co-development agreement with Medarex for antibody therapeutics, collaborations with Teva covering toxicity biomarkers and with Mayo Clinic covering biomarkers for high risk cardiovascular disease, the discovery of approximately 200,000 medium- and large-scale genetic variations and eight novel ligands for GPCRs, and the expansion of our immunoassay diagnostic agreement with Biosite,” Mr. Kotzer continued. “This unparalleled level of productivity and diversity in drug and diagnostic discovery is possible only because of our discovery engine approach based on the capabilities and understandings that have been developed over the past decade at Compugen,” Mr. Kotzer concluded.
As previously projected, there were no revenues for the first quarter of 2007 (compared to $200,000 for the first quarter of 2006). The net loss for the quarter was $3.1 million (including a non-cash expense of $821,000 related to stock based compensation), or $0.11 per share, compared with a net loss of $3.1 million (including a non-cash expenses of $547,000 related to stock based compensation), or $0.11 per share, for the corresponding quarter of 2006.
Research and development expenses of $2.5 million for the first quarter of 2007, compared to $2.7 million for the first quarter of 2006, remain the Company’s largest expense. These amounts are before the deduction of governmental and other grants, which totaled $297,000 for the first quarter ended March 31, 2007, compared with $417,000 for the corresponding quarter in 2006.
As of March 31, 2007, Compugen had $23.5 million in cash, cash equivalents, deposits and marketable securities, a decrease of $2.9 million from December 31, 2006.
Compugen will hold a conference call to discuss its first quarter results on May 1, 2007 at 10:00 a.m. EST. To access the conference call, please dial 1-888-281-1167 from the US or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen’s website, located at www.cgen.com.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5901. The replay will be available until 12 noon EST on May 3, 2007.